Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine

Biopharmaceutics and Drug Disposition

Volumn 19, Issue 4, 1998, Pages 273-277

  Kwak, Mi K ^a   Lee, Woo I ^a   Kim, Nak D ^a   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

Author keywords

2 (allylthio)pyrazine; Acetaminophen; Cysteine conjugates of acetaminophen; Glucuronide; Glutathione; Mercapturate; Sulphate

Indexed keywords

2 (ALLYLTHIO)PYRAZINE; CYSTEINE CONJUGATE; GLUCURONIDE; GLUTATHIONE; PARACETAMOL; SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DETOXIFICATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; MALE; METABOLIC DETOXICATION, DRUG; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031971036     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199805)19:4<273::AID-BDD94>3.0.CO;2-6     Document Type: Article

References (16)

1. M. Black, Acetaminophen hepatoxicity. Annu. Rev. Med., 35, 577-593 (1984).
2. S.D. Nelson, Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin. Liver Dis., 10, 267-278 (1990).
3. J.J. Hjelle and C.D. Klaassen, Glucuronidation and biliary excretion of acetaminophen in rats. J. Pharmacol. Exp. Ther., 228, 407-413 (1984).
4. J.R. Mitchell, D.J. Jollow, W.Z. Potter, J.R. Gillet and B.B. Brodie, Acetaminophen-induced hepatic necrosis IV. Protective role of glutathione. J. Pharmacol. Exp. Ther., 187, 211-217 (1973).
5. B. Coles, I. Wilson, P. Wardman, J.A. Hinson, S.D. Nelson and B. Ketterer, The spontaneous and enzymatic reactions of N-acetyl-p-benzoquinoneimine with glutathione: a stopped-flow kinetic study. Arch. Biochem. Biophys., 264, 253-260 (1988).
6. D.r. Koop, B.L. Crumpo, G.D. Nordbloom and M.J. Coon, Immunochemical evidence for induction of the alcohol-oxidizing cytochrome P450 of liver microsomes by diverse agents: ethanol, imidazole, trichloroethylene, acetone, pyrazole and isoniazid. Proc. Natl. Acad. Sci. USA, 82, 4065-4069 (1985).
7. N.D. Kim, M.K. Kwak and S.G. Kim, Inhibition of cytochrome P4502E1 expression by 2-(allylthio)pyrazine, a potential chemoprotective agent: Hepatoprotective effects. Biochem. Pharmacol., 53, 261-269 (1997).
8. N.D. Kim, S.G. Kim and M.K. Kwak, Induction of rat hepatic glutathione S-transferases by allyl sulfide, allyl mercaptan, allylmethyl sulfide and 2-(allylthio)pyrazine. In The International Toxicologist, International Congress of Toxicology, 7, 69-P-8, 1995.
9. E.S. Cho, S.H. Chang, J.W. Lee, N.D. Kim and M.G. Lee, Metabolic changes of acetaminophen after intravenous administration to rats pretreated with a hepatoprotective agent, YH-439. Res. Commun. Mol. Pathol. Pharmacol., 91, 3-16 (1996).
10. S.H. Jang, M.H. Lee and M.G, Lee, Pharmacokinetics of etaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. J. Pharm. Sci., 83, 810-814 (1994).
11. J. Liu, Y. Liu, C. Madhu and D. Klaassen, Protective effect of oleanolic acid on acetaminophen-induced hepatotoxicity in mice. J. Pharmacol. Exp. Ther., 266, 1607-1613 (1993).
12. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd edn, Dekker, New York, 1982.
13. S.H. Kim, Y.M. Choi and M.G. Lee, Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm., 21, 1-17 (1993).
14. W.L. Chiou, New calculation method of mean total body clearance of drugs and its application to rationale regimens. J. Pharm. Sci., 69, 90-91 (1980).
15. W.L. Chiou, New calculation method for the apparent drug volume of distribution and application to rational dosage regimens. J. Pharm. Sci., 68, 1067-1069 (1979).
16. F.B. Batman, W.A. Colbum, H.G. Boxenbaum, H.N. Posmanter, R.E. Weinfeld, R. Ronfeld, L. Weissman, J.D. Moore, M. Gibaldi and S.A. Kaplan, Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects, J. Pharmacokinet. Biopharm., 5, 481-494 (1977).